cancer testis antigens are expressed in less than 20% of epithelial tumors, and colorectal tumors exhibit the lowest frequency of expression ( 4 ) , rendering them suboptimal targets in that disease and limiting their clinical use.
An unexplored variation on this theme exploits the universal expression of mucosa-restricted antigens by mucosal tumors, in the context of the established asymmetry in immunologic cross talk between mucosal and systemic compartments ( 5 ) . This asymmetry offers unique advantages that refl ect the intersection of immunologic privilege and immunologic partitioning. Specifi cally, immunologic privilege may limit systemic tolerance to mucosal antigens and facilitate therapeutic antitumor responses, whereas immunologic partitioning may shield mucosae from systemic immune responses and limit autoimmunity ( 6 -9 ) .
Guanylyl cyclase C (GCC), the receptor for diarrheagenic bacterial heat-stable enterotoxins and the endogenous paracrine hormones guanylin and uroguanylin ( 10 ) , is expressed in apical membranes of intestinal epithelial cells, restricting it to mucosal immune compartments ( 11 -14 ) . Moreover, GCC is universally expressed by primary and metastatic colorectal tumors ( 11 -13 , 15 , 16 ) . This pattern of expression suggests that GCC may qualify as an effi cacious mucosa-restricted immunotherapeutic target in colorectal cancer, the second leading cause of cancer mortality in the United States and the fourth most common worldwide ( 17 ) . Here, we defi ne the immunogenicity and therapeutic utility of GCC in mouse models of metastatic colorectal cancer.
Materials and Methods

Guanylyl Cyclase Alignment
Mouse GCA (Genbank accession number NP _032753), GCB (NP_776149), GCC (NP_659504), GCE (NP_032218.2), GCF (NP_001007577), GCG (NP_001074545.1), and NPR3 (NP_ 001034270.1) were aligned using the CLUSTAL W algorithm ( 18 ) . Mice C57BL/6 (n = 30) and BALB/c mice (n = 197) were obtained from the National Cancer Institute (NCI) Animal Production Program (Frederick, MD). GCC-deficient (GCC -/ -) mice ( 19 ) were backcrossed with C57BL/6 mice for more than 10 generations to produce GCC -/ -congenic C57BL/6 mice and wild-type (GCC +/+ ) littermates ( 20 ) . Mouse protocols were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee.
Plasmids
A truncated GCC construct (GCC ECD ) containing the extracellular ligand-binding domain and a C-terminus hexahistidine tag was generated by polymerase chain reaction (PCR) using GCC cDNA and subcloned to produce recombinant viruses. The membranebound recombinant GCC construct, GCC TM , was produced by PCR using the extracellular ligand-binding domain (residues 23 -430) containing an N-terminus pentahistidine tag. The N-terminus signal peptide (residues 1 -23) and C-terminus transmembrane domain (residues 431 -461) containing a C-terminus hexahistidine tag were then added by PCR and subcloned into pMSCV2.2-Puro to generate the plasmid GCC TM -pMSCV2.2-Puro.
Recombinant Viruses
Replication-deficient human type 5 recombinant adenovirus (AV) was generated using the ViraPower Adenoviral Expression System and plasmid pAd/CMV/V5-DEST (Invitrogen, Carlsbad, CA). Adenovirus was purified using the Adeno-X Virus Purification Kit (Clontech, Mountain View, CA) and titered using the Adeno-X Rapid Titer Kit (Clontech). LacZ-AV was acquired from Clontech (LacZ-Adeno-X), expanded, purified, and titered in parallel with GCC ECD -AV. GCC ECD -rabies virus (RV) and control RV were generated using the BsiWI/Nhe restriction sites in the SPBN rabies virus backbone, and infectious virus was recovered as described previously ( 21 ) . The control RV (RV-NP/SIIN) was described previously ( 22 ) . GCC ECD -vaccinia virus (VV) was generated using the pSC11 vaccinia plasmid ( 23 ) . The control VV (VV-1686) was described previously ( 24 ) . Mice were immunized with 1 × 10 8 infectious units (IFU) of adenovirus or 1 × 10 7 foci-forming units (FFU) of rabies virus by intramuscular injection of the anterior tibialis or with 1 × 10 7 plaque-forming units (PFU) of vaccinia virus by intraperitoneal injection (n = 322 AV, n = 10 AV and VV, n = 58 AV, RV, and VV).
Cell Lines C57BL/6-derived MC38 colorectal cancer cells were provided by Jeffrey Schlom (NCI, National Institutes of Health, Bethesda, MD). BALB/c-derived CT26 colorectal cancer cells were from the American Type Culture Collection (Manassas, VA). Both cell lines lack endogenous GCC expression, as determined by radiolabeled ligand binding and quantitative reverse transcriptase -PCR. Stable CT26-GCC TM cell lines were generated by transducing CT26 cells with retrovirus produced from 293T cells that were transiently transfected with pCL-Ampho (Imgenex, San Diego, CA) and GCC TM -pMSCV2.2-Puro, followed by antibiotic selection. GCC TM expression was quantified by fluorescence activated cell sorting (FACS) analysis after staining for the extracellular pentahistidine on GCC TM using mouse monoclonal anti -pentahistidine-Alexa 488
CONTEXT AND CAVEATS
Prior knowledge
Guanylyl cyclase C (GCC) is a protein that is expressed in the cells that line the normal intestine and by metastatic colorectal cancer cells.
Study design
Mouse models of colon cancer were used to test the immunotherapeutic efficacy of GCC.
Contributions
Mice that were immunized with GCC had fewer colon cancer metastases to the liver and lungs and survived longer than controlimmunized mice. No autoimmunity was observed.
Implication
GCC is a potential therapeutic target for metastatic colon cancer.
Limitations
The study used cell lines and mouse models of cancer. It is unknown whether the same results would be observed in human cancer.
antibody (Qiagen, Valencia, CA) and by binding of radiolabeled heat-stable enterotoxin (ST) to purified membranes ( 25 ) .
GCC ECD Protein Purification
Hexahistidine-tagged GCC ECD (GCC ECD -6xHis) was purified from supernatants of 293A cells that had been transduced with GCC ECD -AV using Ni-NTA agarose beads (Qiagen). A baculovirus expression system was used to produce a hexahistidine-tagged signal peptide-deficient GCC extracellular domain protein (GCC 23 -430 ) using the transfer vector pVL1393 and the Sapphire Baculovirus DNA Kit (Orbigen, San Diego, CA). Baculovirus-produced GCC ECD -6xHis was purified using Ni-NTA agarose beads (Qiagen). 293A-expressed GCC ECD was used in enzyme-linked immunosorbent assays (ELISAs), and baculovirus-expressed GCC ECD was used in CD4 + T-cell assays.
Antigen-Specific IgG Antibody Detection by
Enzyme-Linked Immunosorbent Assay BALB/c mice were naive (n = 4) or immunized with control AV (n = 4) or GCC ECD -AV (n = 4), and GCC +/+ (+/+) and GCC -/ -( Ϫ / Ϫ ) C57BL/6 mice were immunized with control AV (n = 4+/+ and n = 4 Ϫ / Ϫ ), GCC ECD -AV (n = 4+/+ and n = 4 Ϫ / Ϫ ), or an irrelevant GST-fusion protein as a negative control (n = 3+/+ and n = 3 -/ -). Mice were killed by CO 2 asphyxiation, and serum was collected 10 -14 days after immunization. Immunosorbent plates (Nunc, Rochester, NY) were coated with purified GCC ECD -6xHis at 10 µ g/mL or with irrelevant adenoviral particles at 1 × 10 7 IFU/mL to detect GCC ECD -specific or AV-specific responses, respectively. Coated plates were incubated with serum or with mouse antipentahistidine IgG (Qiagen) as a positive control. Specific antibodies were detected with HRP-conjugated goat anti -mouse immunoglobulin ( Jackson Laboratories, Bar Harbor, ME) and ABTS substrate (Pierce, Rockford, IL). Data represent the mean absorbance at 405 nm of individual mice.
Antigen-Specific T-Cell Response Detection by IFN[gamma] ELISpot
BALB/c mice were immunized with control AV (n = 16) or GCC ECD -AV (n = 16), and GCC +/+ (+/+) and GCC -/ -( Ϫ / Ϫ ) C57BL/6 mice were immunized with control AV (n = 24+/+ and n = 12 Ϫ / Ϫ ) or GCC ECD -AV (n = 32+/+ and n = 20 Ϫ / Ϫ ). Mice were killed by CO 2 asphyxiation, and spleens were collected 10 days after immunization. Mice were assayed by pooling spleens from two mice per experiment and assaying in triplicate. Data are representative of 2 -6 independent experiments, as indicated in figure legends. Multiscreen filtration plates (Millipore, Billerica, MA) were coated with antimouse interferon gamma (IFN ␥ ) -capture antibody (BD Pharmingen, San Jose, CA). To assay CD8 + T-cell responses, splenocytes or CD8 + T cells that had been separated from splenocytes by magnetic activated cell sorting (MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany) were plated at 10 000 -250 000 effector cells per well and incubated with stimulator cells (MC38 for C57BL/6 mice or CT26 for BALB/c mice). To measure GCC ECD or ␤ -galactosidase -specific responses, stimulator cells were transduced with replicationdeficient GCC ECD -or LacZ-adenovirus, respectively, at a multiplicity of infection of 500 (MC38) or 100 (CT26) and treated with 1000 U/mL recombinant mouse IFN ␥ (EMD Biosciences, San Diego, CA) for 48 hours to increase MHC expression. To assay CD4 + T-cell responses, MACS-sorted CD4 + T cells (Miltenyi Biotec) were mixed with naive splenocytes as antigen presenting cells and incubated on antibody-coated plates with GCC ECD -6xHis (0 -100 µ g/mL) or irrelevant purified adenovirus particles (0 -1 × 10 8 IFU/ mL) to measure GCC ECD -specific or AV-specific responses, respectively. After 24 -28 hours of stimulation, cells were removed by washing, and spots were developed with biotinylated anti-IFN ␥ detection antibody (BD Pharmingen) and alkaline phosphataseconjugated streptavidin (Pierce), followed by Nitro-Blue Tetrazolium Chloride and 5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt substrate (Pierce). Spot numbers were quantified using computer-assisted video imaging analysis (ImmunoSpot v3, Cellular Technology, Shaker Heights, OH). Data are reported as spots (IFN ␥ -producing cells) per 10 6 cells or per well.
GCC Immunization Against Subcutaneous Colon Tumors
BALB/c mice received a prophylactic immunization with AV (n = 5 control and GCC ECD ), with AV and VV at 28-day intervals (n = 5 control and GCC ECD ), or with AV, RV, and VV at 28-day intervals (n = 7 -8 control and GCC ECD ). Subcutaneous tumors were then established on the flanks of mice with 1 × 10 5 CT26-GCC TM cells 1 week after the final immunization, and tumor growth was quantified twice a week for 45 days by measuring three orthogonal diameters and calculating volumes using: 4/3 p × r 1 × r 2 × r 3 , in which ( r ) is half the diameter. For survival analysis, mice were killed by CO 2 asphyxiation when tumors achieved a volume of 1200 mm 3 , a surrogate endpoint used in compliance with institutional animal care guidelines. Twenty-one days was selected as the maximum for the growth curves because most control mice reached the survival endpoint around day 25.
GCC Immunization Against Colon Cancer
Metastases to Liver BALB/c mice were immunized with control AV (n = 11) or GCC ECD -AV (n = 12). Liver metastases were established by injecting 1 × 10 5 CT26-GCC TM cells into the exteriorized spleens of mice 7 days after immunization ( 26 ) . Mice were killed by CO 2 asphyxiation, and metastases were counted in excised livers 21 days after tumor challenge.
GCC Immunization Against Colon Cancer Metastases to Lung
To examine prophylaxis, BALB/c mice were immunized with control AV (n = 21) or GCC ECD -AV (n = 31), and lung metastases were established by injecting 5 × 10 5 CT26-GCC TM cells into the tail veins of mice 7 days after immunization. Some mice (n = 14) were imaged by positron emission tomography (PET) and micro computer tomography (CT) 14 days later, then killed by CO 2 asphyxiation, and metastases were counted ( 27 ) . Other mice (n = 36) were monitored for survival daily for 45 days. In studies of therapeutic immunization, lung metastases were established in BALB/c mice (n = 39) by tail vein injection with 1 × 10 5 CT26-GCC TM cells. Mice were then immunized with control (n = 22) or GCC ECD (n = 17) AV on day 3, followed by sequential boosting with RV and VV every 12 -26 days such that most mice received all three immunizations before dying from metastasis growth. Survival was monitored and recorded daily for 55 days.
PET/Micro CT Metastasis Quantification
Mice were immunized with control AV (n = 5) or GCC ECD -AV (n = 9) 7 days before being injected by tail vein with 5 × 10 5 GCC TM cells. Fourteen days later, mice received 0.45 mCi 18 F-fluorodeoxyglucose by tail vein, and PET images were collected 2 hours later on a Mosaic scanner (Philips Medical Systems, Andover, MA). CT images were acquired on a micro-CAT II (Imtek, Inc, Knoxville, TN). For quantification of 18 F-fluorodeoxyglucose uptake and, consequently, tumor burden, a volumetric region of interest was defined in the lungs. Using calibration parameters that were derived from a cylinder of known size and activity, absolute quantification values of percent of injected dose per g of tissue were calculated. Average lung values were normalized to uptake in liver within each mouse (lung minus liver).
Detection of Serum Antinuclear Antibodies
Antinuclear antibodies were quantified in serum using an anti -ANA ELISA Kit (Alpha Diagnostics, San Antonio, TX) in C57BL/6 mice 10 days after immunization with LacZ-AV (n = 6) or GCC ECD -AV (n = 6). Serum from 8-week-old male MRL/MpJ-Fas lpr /J mice ( Jackson Laboratories) (n = 3) served as positive controls, and serum from naïve mice (n = 2) served as negative controls. Antinuclear IgG was quantified using a standard curve and reported as micrograms of IgG per milliliter.
Autoimmune Pathology
Chemistry profiles were commercially determined (Charles River Laboratories, Wilmington, MA) on fresh serum from previously immunized GCC +/+ (n = 5 control AV and n = 6 GCC ECD -AV) and GCC -/ -(n = 6 control AV and n = 5 GCC ECD -AV) mice. Tissues from immunized BALB/c mice (n = 3 for each immunization) were formalin-fixed, paraffin-embedded, stained by hematoxylin and eosin, blindly labeled, and analyzed by a pathologist (R. Birbe).
Statistical Analyses
Cohort sizes were selected to provide 80% power to detect twofold differences between groups. Survival analysis used Mantel -Haenszel log-rank test (GraphPad Prism Software, San Diego, CA). Twoway analysis of variance (GraphPad Prism) was used for subcutaneous tumor growth studies, antigen-specific antibody assays, and T-cell assays. Student t test or Welch t test (for tests with unequal intergroup variances) were used for all other statistical analyses. All statistical tests were two-sided. P values less than .05 were considered statistically significant.
Results
Vaccine Strategy
The seven members of the particulate guanylyl cyclase family have a canonical structure with highly homologous cytoplasmic catalytic and regulatory domains and extracellular domains possessing minimal sequence homology, reflecting the diversity of their cognate peptide ligands ( 14 ) ( Figure 1, A ) . Conservation of cytoplasmic domains among isoforms ( Figure 1, B ) and the broad tissue distribution of guanylyl cyclases A, B, and G identified the extracellular ligand-binding domain of GCC as the only unique segment of the molecule, therefore focusing vaccine generation on only the GCC extracellular ligand-binding domain. Because none of the established mouse cell lines express endogenous GCC, CT26 mouse colon cancer cells were transduced with a retrovirus containing a recombinant mouse GCC ( Figure 1, C ) , which was truncated beyond the transmembrane domain and lacked intracellular domains (GCC TM ; Figure 1 , B ), at expression levels within the range of normal murine enterocytes and human colon cancer cells ( Figure 1, D ) . Viral vaccine vectors were constructed to express a secreted form of GCC that was truncated beyond the ligand-binding domain and lacked transmembrane and intracellular domains (GCC ECD ; Figure 1 , B ). We used constructs containing the nonhomologous (unique) extracellular domain because the full-length molecule has homology with the cytoplasmic domains of other guanylyl cyclases. Prophylactic guanylyl cyclase C (GCC) -specifi c immunity against subcutaneous colon tumor progression. BALB/c mice were prophylactically immunized with recombinant viruses expressing the extracellular domain of GCC (GCC ECD ) or control viruses using an escalating heterologous prime-boost strategy and were then injected on day 0 with 1 × 10 5 CT26-GCC TM cells. A ) Adenovirus (AV). B ) AV followed by vaccinia virus (VV). C ) AV followed sequentially by rabies virus (RV) and VV. Data in ( A -C ) are means of n = 5 -8 mice per immunization, and error bars indicate 95% confi dence intervals (*** P < .001, two-way analysis of variance of tumor growth in control-vs GCC ECD -immunized mice). D ) Images of control and GCC ECD AV-RV-VV -immunized mice on day 24 with tumors in control mice outlined for clarity. E ) Survival analysis of mice from ( B ) ( P = .018, two-sided Mantel -Haenszel log-rank test) in which a tumor volume greater than 1200 mm 3 was used as a surrogate endpoint for death. F ) Survival analysis of mice from ( C ) ( P < .001, two-sided Mantel -Haenszel log-rank test), in which a tumor volume greater than 1200 mm 3 was used as a surrogate endpoint for death. Solid lines in ( E ) and ( F ) indicate percent survival; dashed lines indicate 95% confi dence intervals.
Prophylactic GCC Immunotherapy Against Subcutaneous Colon Tumors BALB/c mice received a prophylactic immunization comprising an escalating heterologous prime-boost regimen of replicationdeficient recombinant adenovirus, recombinant attenuated rabies virus, and recombinant vaccinia virus, with 28 days between each immunization. Seven days after the last immunization, mice were subcutaneously injected with 1 × 10 5 CT26 mouse colon carcinoma cells expressing GCC TM (CT26-GCC TM cells), and tumor volume was monitored for 21 days. A single immunization with GCC ECD -AV did not alter the growth of CT26-GCC TM cells compared with a control AV immunization ( Figure 2, A ) . However, a prophylactic heterologous prime-boost strategy using GCC ECD -AV followed by GCC ECD -VV reduced tumor growth ( Figure 2 
Prophylactic and Therapeutic GCC Immunotherapy Against Parenchymal Colon Cancer Metastases
More than 50% of patients with colorectal cancer die of metastatic disease, primarily in liver and lung ( 5 ) . To mimic human disease in parenchymal metastasis models, mice were administered 1 × 10 5 CT26-GCC TM cells by intrasplenic injection to establish liver metastases 7 days after immunization with GCC ECD -expressing or control AV. Three weeks later, livers were collected and tumor burden was quantified by counting nodules and measuring liver wet weight, a marker of metastatic disease. In contrast to efficacy against subcutaneous tumor growth, immunization with GCC ECD -AV alone reduced the formation of liver nodules by approximately 90% ( Figure 3 , A and C ; control AV vs GCC ECD -AV: 30.4 vs 3.55 nodules, difference = 26.9 nodules, 95% CI = 8.47 to 45.3 nodules, P = .008) and liver wet weight by 25% ( Figure 3 
CD8
+ T Cells, but Not CD4 + T Cells or Antibodies, as Mediators of GCC-Targeted Immunity Protection against metastatic tumor cells by immunization with recombinant viruses presumably reflects mucosal compartmentalization of GCC expression, resulting in incomplete systemic tolerance and selected immune cell responses to that antigen. Immunization of BALB/c mice with GCC ECD -AV or LacZ-AV elicited AV-specific, but not GCC-specific, IgG responses ( Figure 5, A and B ) . Similarly, AV-specific, but not GCC-specific, Th1 CD4 + T-cell responses were induced in immunized mice ( Figure 5, C and D ) . In contrast, antigenspecific CD8 + T-cell responses directed against ␤ -galactosidase (LacZ), a foreign antigen, or GCC were nearly equivalent ( + T-cell responses in GCC -/ -mice following immunization with GCC ECD -AV underscore the antigenic competence of GCC to induce responses in all arms of the adaptive immune system. In contrast, incomplete tolerance to GCC in wild-type BALB/c and C57BL/6 mice reflects mucosal partitioning and restricted crosscompartmental antigen availability ( 30 , 31 ) .
Antitumor Immunity Without Collateral Autoimmune Disease
The established restriction of immunologic cross talk between systemic and mucosal compartments in conjunction with systemic tolerance in CD4 + T-cell responses to mucosa-restricted antigens identified herein should limit autoimmune disease in response to GCC-based immunization. Mice that were serially immunized with three viruses encoding GCC ECD and exhibiting maximum antitumor responses (see Figure 2 , C, D, and F ) were healthy, with no signs or symptoms of inflammatory bowel disease, including weight loss, failure to thrive, altered bowel habits, or rectal bleeding. Similarly, GCC +/+ and GCC -/ -mice that were immunized with GCC ECD -AV exhibited normal organ and metabolic function, as quantified by serum chemistries ( Table 1 ) . Further, autoimmune-mediated tissue damage, which was quantified by serum antinuclear antibodies, was absent in GCC +/+ mice that were immunized with GCC ECD -AV ( Figure 7, A ) . Moreover, the gastrointestinal tract, lungs, liver, and kidneys of mice that were serially immunized with three viruses encoding GCC ECD exhibiting maximum antitumor responses were free of damage and immune cell infiltration ( Figure 7, B effective concomitant antitumor immunity revealed an absence of adverse effects induced by GCC immunotherapy.
In contrast to currently available cancer testis antigens, the universal expression of mucosa-restricted antigens by derivative tumors offers a unique solution to the application of self-antigens from immunologically privileged sites to tumor immunotherapy. This approach leverages the established immunologic partitioning of systemic and mucosal compartments ( 6 -9 ) . Asymmetry in signaling across compartments, wherein systemic immune responses rarely extend to mucosae, limits the risk of autoimmunity following systemic immunization. Conversely, expression that is restricted to mucosae limits antigen access to the systemic compartment and opposes tolerance to mucosal antigens and, therefore, may overcome the inherent limitations of immunotherapy directed to selfantigens. However, systemic tolerance to mucosa-restricted antigens, which can limit antitumor effi cacy, has been only incompletely defi ned. Here, immunization revealed lineage-specifi c Tcell tolerance in the systemic compartment, which contained CD8 + T-cell responses, but not CD4 + T-cell responses, to GCC. Tolerance refl ects thymic and/or peripheral mechanisms rather than antigenicity, because GCC -/-mice responded to GCC in all arms of the adaptive immune system, whereas in two strains of GCC +/+ mice GCC elicited only CD8 + T-cell responses. Incomplete central tolerance to GCC presumably refl ects anatomical, functional, and immunologic compartmentalization wherein sequestration of mucosal antigens provides insuffi cient antigen for complete systemic tolerance ( 30 , 31 ) .
In that context, common molecular mechanisms mediating incomplete systemic tolerance to mucosal antigens have not yet emerged. Indeed, tolerance to the gastric-specifi c H + /K + -ATPase is mediated peripherally ( 32 ) and that to a mucosa-selective carcinoembryonic antigen transgene is mediated by the thymus ( 33 ) . Here, incomplete tolerance may refl ect CD4 + T-cell -independent induction of antigen-specifi c CD8 + T-cell responses ( 34 ) . Alternatively, virus-specifi c CD4 + T cells may provide suffi cient support to develop effi cacious GCC-specifi c CD8 + T-cell responses + T-cell responses in +/+ and Ϫ / Ϫ C57BL/6 mice following GCC ECD -AV immunization measured by IFN ␥ ELISpot. Data indicate pooled analysis of n = 2 mice per group, and error bars indicate 95% CIs of two independent experiments (* P = .019, two-way ANOVA). ( 35 ) . Incomplete tolerance may be mediated, in part, by AIREregulated peripheral antigen expression within thymic epithelial cells, resulting in T-cell deletion ( 36 , 37 ) . In addition, intestinal antigens may be acquired by mucosal dendritic cells and transported to mesenteric lymph nodes, where they induce regulatory CD4 + CD25 + T cells, deletion/anergy of naive T cells, or other mechanisms that diminish immune responsiveness to GCC ( 38 , 39 ) . Although mechanisms that mediate incomplete systemic tolerance remain to be defi ned, these advantageous immune cell responses underscore the potential of cancer mucosa antigens as immunotherapeutic targets to prevent tumor metastases in the absence of collateral autoimmune tissue damage.
GCC immunization produced effective antitumor immune responses likely mediated by CD8 + T cells in the systemic compartment in the absence of mucosal autoimmune disease, refl ecting compartment-restricted lymphocyte recirculation imprinted by tissue-specifi c activation ( 6 , 7 , 40 -43 ) . T cells that are activated in mesenteric lymph nodes home to lymphoid structures that are associated with the gut wall, including the lamina propria and Peyer ' s patches, and those that are activated systemically home primarily to the spleen and to peripheral lymph nodes and associated tissues ( 41 -44 ) . Compartmentalized recirculation reciprocally increases the effi ciency of regional immune responses while decreasing tissue antigen cross-reactivity ( 41 ) . In that context, the functional independence of compartments is refl ected by the paucity of mucosal responses to systemic immunization ( 6 -9 ). Here, this functional independence, wherein systemic immune responses rarely extend to the mucosal compartment, has been exploited to generate therapeutic responses to metastatic cancer without collateral autoimmune disease by using a self-antigen whose expression is normally restricted to mucosa but is universally expressed in metastatic colorectal tumors.
In the scope of current clinical practice and management of patients with colorectal cancer, vaccination using cancer mucosa antigens generally, and GCC specifi cally, should have the greatest impact on survival in patients who are at risk for developing metastatic disease. Patients who are ostensibly free of regional metastases at the time of diagnosis and staging (tumor, node and metastases [TNM] stages 1, 2) are at substantial risk for developing metastatic disease, refl ecting the presence of occult micrometastases ( 17 ). In this clinically heterogeneous population, some of whom have occult residual disease, adjuvant immunotherapy could reduce recurrences and extend disease-free survival, refl ecting maximum therapeutic effi cacy in the context of minimal metastatic tumor burden. Similarly, cancer mucosa antigen vaccines could impact fl uoropyrimidine-based adjuvant therapeutic regimens, which are the mainstay for patients with TNM stage 3 disease with regional lymph node metastases ( 17 ) . Further, GCC-based vaccines might improve clinical outcomes in patients with esophageal and gastric cancer, refl ecting the role of intestinal metaplasia and the associated novel ectopic expression of that antigen in those malignancies ( 45 ) . Moreover, the effi cacy of adjuvant immunotherapy in gastrointestinal malignancies might benefi t from polyvalent vaccines that incorporate cancer mucosa antigens other than GCC, for example, Cdx2 and sucrase-isomaltase, which also are intestinally restricted and highly expressed in mucosa-derived malignancies.
These observations establish a framework for exploiting immunologic compartmentalization beyond the gastrointestinal tract to achieve antimetastatic therapy in tumors that originate from other mucosae, including oral, respiratory, mammary, and urogenital, for the treatment of cancers of the head and neck, lung, breast, and vagina and bladder, respectively. This potential for cancer mucosa antigens as immunotherapeutic targets highlights the gap in understanding mechanisms underlying systemic and peripheral tolerance and the segregation of adaptive immune responses across mucosae. Those considerations notwithstanding, the overarching principles of immunologic compartmentalization apply outside the gastrointestinal tract wherein systemic immune responses do not extend to extraintestinal mucosal surfaces ( 8 , 46 ) . The established principles of immune partitioning in the context of the present results with GCC underscore the importance of defi ning the generalizability of cancer mucosa antigens as targets for immunotherapy of mucosa-derived tumors.
Limitations in this study relate to cell lines and mice as preclinical models of human malignancy. Cell lines may not accurately refl ect the spectrum of antigen presentation or immunogenicity exhibited by human tumors. Also, the CT26 mouse tumor cell line used herein was genetically engineered to express GCC, albeit at levels comparable with those endogenously expressed in normal mouse intestinal cells and human tumor cells. Further, subcutaneous and parenchymal tumor metastasis models in mice may incompletely refl ect the pathophysiology and immunology of metastatic disease in patients. Moreover, although observational data suggest the compartmentalization of mucosal and systemic immunity, its relevance and underlying mechanistic contribution to antitumor immunotherapy in humans are unknown. In addition, the immunogenicity of GCC in humans is not yet known. Finally, the generalizability of cancer mucosa antigens across different vaccine targets and mucosae for immunotherapy in animals and humans remains to be defi ned.
